Eli Lilly and Company

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2025-02-07 pm EST			After market 07:56:38 pm
878.31 ^USD	+0.91%		880.94	+0.30%

Feb. 07	Sector Update: Health Care Stocks Lower in Late Afternoon Trading	MT
Feb. 07	Sector Update: Health Care Stocks Lower Friday Afternoon	MT

Eli Lilly CEO on Fighting Cancer and Obesity, Drug Pricing

January 13, 2025 at 11:30 am EST

Eli Lilly & Co. (LLY) Chief Executive Officer Dave Ricks talks about paying $2.5 billion for a cancer drug being developed by Scorpion Therapeutics. He also says Lilly's experimental weight-loss pill could be approved in early 2026. He speaks to Bloomberg from the JPMorgan Healthcare Conference in San Francisco.

Bloomberg videos, provided by MT Newswires

Latest news about Eli Lilly and Company

Sector Update: Health Care Stocks Lower in Late Afternoon Trading	Feb. 07	MT
Sector Update: Health Care Stocks Lower Friday Afternoon	Feb. 07	MT
Sector Update: Health Care	Feb. 07	MT
Leerink Partners Adjusts Eli Lilly and Company's Price Target to $989 From $950	Feb. 07	MT
Eli Lilly: promising results in Crohn's disease	Feb. 07	CF
The Employment Enigma	Feb. 07
Eli Lilly Reports Sustained Clinical Remission, Endoscopic Response in Patients With Crohn's Disease Treated With Omvoh	Feb. 07	MT
Eli Lilly Says Most Patients On Omvoh® For Crohn's Disease Achieved Remission And Endoscopic Response At Two Years	Feb. 07	RE
Eli Lilly and Company Announces Results from the VIVID-2 Open-Label Extension Study	Feb. 07	CI
Analysts recommendations: Aj Bell, GSK, Anglo American, Eli Lilly, Expedia…	Feb. 07
Analysts recommendations: Air Products & Chemicals, AMD, Elf Beauty, Eli Lilly, Expedia…	Feb. 07
Health Care Climbs After Lilly Earnings - Health Care Roundup	Feb. 06	DJ
Sector Update: Health Care Stocks Slide Late Afternoon	Feb. 06	MT
Wall Street ends mixed in choppy trading; Amazon, jobs report in focus	Feb. 06	RE
Sector Update: Health Care	Feb. 06	MT
Eli Lilly Fourth-Quarter Sales Meet Views; Reiterates 2025 Revenue Forecast	Feb. 06	MT
Lilly's profit forecast brings relief amid Zepbound miss	Feb. 06	RE
Lilly Exec Says U.S. Zepbound Performance Is Going Very Well	Feb. 06	RE
S&P 500, Nasdaq rise on earnings reports; Trump, Fed policy in focus	Feb. 06	RE
Global markets live: Honeywell International, Eli Lilly, Alphabet, Ford, Carlsberg…	Feb. 06
Wall St ticks higher as big corporate earnings lift sentiment	Feb. 06	RE
Eli Lilly and Company, Q4 2024 Earnings Call, Feb 06, 2025	Feb. 06
The stock market just won't go down	Feb. 06
Sector Update: Health Care Stocks Flat to Higher Pre-Bell Thursday	Feb. 06	MT
Wall St set for muted open after big corporate results; Honeywell dips	Feb. 06	RE

Chart Eli Lilly and Company

Duration

Period

LLY: Dynamic Chart

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).

Employees

43,000

Sector

Pharmaceuticals

Calendar

2025-02-13 - Détachement de

More about the company